FDA's Risk-Based Inspection Shift: What It Actually Rewards

By Meg Sinclair

The FDA revised Compliance Program 7346.832 for pre-approval inspections, establishing a risk-based evaluation framework to determine whether onsite inspections are necessary. When marketing applications are submitted, Integrated Quality Assessment teams evaluate facility history, product risks, and compliance signals to decide if on-site visits are warranted or if alternative methods, such as remote regulatory assessments or partner inspection reports, suffice.

This structural shift penalizes temporary pre-inspection preparation sprints and rewards facilities maintaining continuous audit readiness. Relying on spreadsheets or short-term consultant audits leaves life sciences companies vulnerable when risk assessments occur without advance warning. Review your CAPA and complaint-handling records to eliminate recurring gaps, evaluate international partner agreements, and transition toward continuous compliance readiness across your manufacturing operations.